Bin T Teh
Overview
Explore the profile of Bin T Teh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
2423
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Zhang Z, Furge K, Yang X, Teh B, Hansel D
BMC Med Genomics
. 2010 Dec;
3:58.
PMID: 21159190
Background: Urothelial carcinoma (UC) can arise at any location along the urothelial tract, including the urethra, bladder, ureter, or renal pelvis. Although tumors arising in these various locations have similar...
22.
Hellenthal N, Underwood W, Penetrante R, Litwin A, Zhang S, Wilding G, et al.
J Urol
. 2010 Jul;
184(3):859-64.
PMID: 20643461
Purpose: Sunitinib is an approved treatment for metastatic renal cell carcinoma. We performed a prospective clinical trial to evaluate the safety and clinical response to sunitinib administered before nephrectomy in...
23.
Hammers H, Verheul H, Salumbides B, Sharma R, Rudek M, Jaspers J, et al.
Mol Cancer Ther
. 2010 May;
9(6):1525-35.
PMID: 20501804
Tyrosine kinase inhibitors (TKI) targeting angiogenesis via inhibition of the vascular endothelial growth factor pathway have changed the medical management of metastatic renal cell carcinoma. Although treatment with TKIs has...
24.
Furge K, MacKeigan J, Teh B
Lancet Oncol
. 2010 Apr;
11(6):571-8.
PMID: 20381423
Renal-cell carcinoma is a heterogeneous group of tumours that arise in the adult kidneys. Irrespective of the type of renal tumour, traditional chemotherapeutic and radiation-based therapies have been largely ineffective...
25.
Bignell G, Greenman C, Davies H, Butler A, Edkins S, Andrews J, et al.
Nature
. 2010 Feb;
463(7283):893-8.
PMID: 20164919
The cancer genome is moulded by the dual processes of somatic mutation and selection. Homozygous deletions in cancer genomes occur over recessive cancer genes, where they can confer selective growth...
26.
Yang Y, Kort E, Ebrahimi N, Zhang Z, Teh B
Cancer Inform
. 2010 Feb;
9:1-9.
PMID: 20148167
Background: Gene set enrichment analysis (GSEA) is an analytic approach which simultaneously reduces the dimensionality of microarray data and enables ready inference of the biological meaning of observed gene expression...
27.
Hahn M, Howell V, Gill A, Clarkson A, Weaire-Buchanan G, Robinson B, et al.
Endocr Relat Cancer
. 2009 Dec;
17(1):273-82.
PMID: 20026646
The tumor suppressor HRPT2/CDC73 is mutated in constitutive DNA from patients with the familial disorder hyperparathyroidism-jaw tumor syndrome and in approximately 70% of all parathyroid carcinomas. In a number of...
28.
Glenn S, Head K, Teh B, Gross K, Kim H
J Biomol Screen
. 2009 Dec;
15(1):80-5.
PMID: 20008123
Formalin-fixed, paraffin-embedded tissues are widely available for gene expression analysis using TaqMan PCR. Five methods, including 4 commercial kits, for recovering RNA from paraffin-embedded renal tumor tissue were compared. The...
29.
Rogers C, Ditlev J, Tan M, Sugimura J, Qian C, Cooper J, et al.
Am J Transl Res
. 2009 Dec;
1(1):55-61.
PMID: 19966938
We investigate the feasibility of using microarray gene expression profiling technology to analyze core biopsies of renal tumors for classification of tumor histology. Core biopsies were obtained ex-vivo from 7...
30.
Farber L, Kort E, Wang P, Chen J, Teh B
Mol Carcinog
. 2009 Nov;
49(3):215-23.
PMID: 19908240
Parafibromin, encoded by the gene HRPT2, is a tumor suppressor protein associated with the RNA polymerase II-associated complex, Paf1 complex. HRPT2 mutations were first identified in patients with the multiple...